Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

CRLF2 Expression in Mexicans with Acute Lymphoblastic Leukemia across the Age Spectrum

Héctor A. Martínez-Espinosa, Nereida Méndez-Ramírez, Julia Colunga Pedraza, Eli Fuentes-Chávez, Rosario Salazar-Riojas, Odra L. Martínez-González, Antonio Vega-Mateos, Oscar Gonzalez Llano, Ingrid López-Reyna, David Gomez-Almaguer, Andres Gomez-De Leon, Vanessa Treviño-Sordia, Roberto Solano-Texta

Blood (2023) 142 (Supplement 1): 6054.

https://doi.org/10.1182/blood-2023-188339

Published: 2023

Journal Articles

Exploring the Efficacy and Feasibility of Outpatient Blinatumomab Short Cycles in Pediatric Patients with Relapsed/Refractory B-ALL in LMIC: Preliminary Results

Julia Esther Colunga Pedraza, Samantha Rodriguez, Ingrid López-Reyna, Lucía Hernández Torres, Perla Rocio Colunga Pedraza, Valeria Fuentes, David Gomez-Almaguer, Yajaira Valentina Jimenez-Antolinez, Oscar Gonzalez Llano

Blood (2023) 142 (Supplement 1): 5813.

https://doi.org/10.1182/blood-2023-190271

Published: 2023

Journal Articles

The Doses of Post-Transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Can be Reduced

Juan Carlos Olivares-Gazca, María de Lourdes Pastelín-Martínez, Merittzel Abigail Montes-Robles, Moisés Manuel Gallardo-Pérez, Edgar Jared Hernández-Flores, Max Robles-Nasta, Daniela Sánchez-Bonilla, César Homero Gutierrez-Aguirre, Andres Gomez-De Leon, David Gomez-Almaguer, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Arguelles

Blood (2023) 142 (Supplement 1): 2173.

https://doi.org/10.1182/blood-2023-181489

Published: 2023

Journal Articles

Optimizing Resources: Low-Dose Nivolumab Combinations in the Management of Relapsed/Refractory Hodgkin Lymphoma, a Real-World Experience

Héctor Alejandro Vaquera Alfaro, Zulia Guzman-Martínez, Antonio Vega-Mateos, Yadith Karina Lopez-Garcia, Ana Cristina Tejada Vasquez, Gerardo Garcia-Salas, César Homero Gutierrez-Aguirre, Olga Cantu, David Gomez-Almaguer, Perla R. Colunga-Pedraza

Blood (2023) 142 (Supplement 1): 1711.

https://doi.org/10.1182/blood-2023-188171

Published: 2023

Journal Articles

Disparities in Phase 3 Leukemia Trials from the Last Decade: A Long Way to Go

Andres Noyola-Perez, Alejandra J. Osuna-Corrales, Manali I. Patel, Jorge Cortes, Lillian Sung, Juan C. Angulo-Lozano, Perla R. Colunga-Pedraza, David Gomez-Almaguer, Guillermo José Ruiz-Arguelles, Andres Gomez-De Leon

Blood (2023) 142 (Supplement 1): 494.

https://doi.org/10.1182/blood-2023-189576

Published: 2023

Journal Articles

Real-World Data on the Clinical Features, Therapy Patterns and Outcomes of 651 Elderly Patients with Diffuse Large B-Cell Lymphoma in Latin America: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2023) 142 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2023-187049

Published: 2023

Journal Articles

Validating the Halp Score (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio ( NLR ) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)

Blood (2023) 142 (Supplement 1): 1757.

https://doi.org/10.1182/blood-2023-188265

Published: 2023

Journal Articles

Outpatient Low-Dose Venetoclax Plus Azacitidine Vs. Intensive Chemotherapy for Newly Diagnosed Fit Patients with Acute Myeloid Leukemia in a Limited Resource Setting

Yadith Karina Lopez-Garcia, Fernando De La Garza, Gerardo Alexis De la Rosa-Flores, Edgar Ulises Coronado Alejandro, Antonio Vega-Mateos, Ana Cristina Tejada Vasquez, Gerardo Garcia-Salas, Valeria García-Zárate, Perla R. Rocio Colunga-Pedraza, David Gomez-Almaguer, Andres Gomez-De Leon

Blood (2023) 142 (Supplement 1): 1529.

https://doi.org/10.1182/blood-2023-188088

Published: 2023

Journal Articles

Lost and Found: A Mixed Methods Study on Treatment Abandonment in Acute Leukemia

Ana Cristina Tejada Vasquez, Eliezer Gomez, Fernando De La Garza, Edgar Ulises Coronado Alejandro, Carlos De La Cruz-De La Cruz, Valeria García-Zárate, Anna Cecilia Rodriguez-Zuñiga, Alexia Sánchez, David Gomez-Almaguer, Andres Gomez-De Leon

Blood (2023) 142 (Supplement 1): 2439.

https://doi.org/10.1182/blood-2023-189645

Published: 2023

Journal Articles

Unlocking Global Potential: Education and Funding Opportunities for International Trainees in Hematology

Lourdes Gil-Flores, Emilia Ramos-Barrera, Andrea Flores-Díaz, Lillian Sung, David Gomez-Almaguer, Andres Gomez-De Leon

Blood (2023) 142 (Supplement 1): 3699.

https://doi.org/10.1182/blood-2023-182261

Published: 2023

Journal Articles

CYP Inhibition and Low-Dose Dasatinib for Chronic Myeloid Leukemia: Preliminary Results of a Promising, Cost-Effective Treatment Option

Juan Francisco Barrios Ruiz, Fernando De La Garza, Victor Mingura Ledezma, Olga Cantu, Ana Cristina Tejada Vasquez, David Gomez-Almaguer, Perla R. Rocio Colunga-Pedraza

Blood (2023) 142 (Supplement 1): 5744.

https://doi.org/10.1182/blood-2023-188215

Published: 2023

Journal Articles

Autologous HSCT for Multiple Sclerosis Should be Done Early in the Course of the Disease

María de Lourdes Pastelín-Martínez, Moisés Manuel Gallardo-Pérez, Andres Gomez-De Leon, Juan Carlos Olivares-Gazca, Edgar Jared Hernández-Flores, Daniela Sánchez-Bonilla, Merittzel Abigail Montes-Robles, Max Robles-Nasta, Guillermo Ocaña-Ramm, Silvia Soto-Olvera, David Gomez-Almaguer, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Arguelles

Blood (2023) 142 (Supplement 1): 3593.

https://doi.org/10.1182/blood-2023-181433

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

Validating the Systemic Inmmune-Inflamation Index (SII) As a Prognostic Biomarker of Overall Survival in Diffuse Large B-Cell Lymphoma: A Retrospective Analyses By the Gruppo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2023) 142 (Supplement 1): 1775.

https://doi.org/10.1182/blood-2023-188015

Published: 2023

Journal Articles

Capizzi Vs HDMTX in the Intermediate Maintenance Phase in Patients with Intermediate-Risk ALL in a 3rd Level Hospital in Northeastern Mexico

Valeria Fuentes, Yajaira Valentina Jimenez-Antolinez, Ginna Mariana Romero-Jacobo, Paulina Garcia - Maldonado, Juan Pablo Ruiz-Padilla, Samantha Carolina Rodriguez- Miranda, Jorge Federico Marcos-Garcia, Julia Esther Colunga Pedraza, David Gomez-Almaguer, Oscar Gonzalez Llano

Blood (2023) 142 (Supplement 1): 5883.

https://doi.org/10.1182/blood-2023-190990

Published: 2023

Journal Articles

Is VTD the Best First Line Therapy for Multiple Myeloma in an Environment with Limited Resources? an Analysis of Outcomes and Costs

Eliezer Tomas Tomas Gomez Gomez, David Gomez Almaguer, Cesar Homero Gutierrez-Aguirre, Perla R.R. Colunga-Pedraza, Luz Tarin-Arzaga, Jose Carlos Jaime, Edgar Ulises Coronado, Fernando De La Garza, Estefania Guadarrama Rendon, Santiago Calzada Davila

Blood (2022) 140 (Supplement 1): 7710–7711.

https://doi.org/10.1182/blood-2022-163772

Published: 2022

Journal Articles

Feasibility and Improvement in Survival with a Risk-Adapted Treatment Regimen for Childhood Acute Lymphoblastic Leukemia in a Limited Resource Setting

Yajaira Valentine Jimenez-Antolinez, Samantha Fierro Sáenz, Lilia Edith Carrizales Torres, Julia Esther Colunga Pedraza, Hernan Ramirez-Duran, Andrés Gómez-De León, David Gómez-Almaguer, Oscar Gonzalez

Blood (2022) 140 (Supplement 1): 6132–6133.

https://doi.org/10.1182/blood-2022-170941

Published: 2022

Journal Articles

Hematopoietic Cell Transplantation in First Remission in AML in Mexico: Very Low Rates Derived from Early Relapses and Lack of Access

Blood (2022) 140 (Supplement 1): 10830–10832.

https://doi.org/10.1182/blood-2022-170200

Published: 2022

Journal Articles

Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup

Humberto Martinez-Cordero, Camila Peña, Natalia Paola Schutz, Virginia Bove, Fiorella Villano, Rocío Osorio, Mauricio Chandia, Cecilia Beltrán, Javier Schulz, Daniela Cardemil, Carolina Contreras, Carmen Gloria Vergara, Javiera Donoso, Marcela Espinoza, Gabriel La Rocca, Hernán López-Vidal, Pilar León, Macarena Roa, Christine Rojas, Pablo Soto, Sandra Aranda, Vivianne Torres, Paola Ochoa, Patricio Duarte, Guillermina Remaggi, Sebastian Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Veronica Verri, Luis Darío Quiroga, Juan Jose Garcia, Vanesa Fernandez, Dorotea Fantl, Jhoanna Ramirez, Alicia Molina, Pilar Papilco, Alex Mite, Ines Reyes, Brenner Sabando Vélez, Francisca M. Ramirez Aspiazu, Claudia Lucia Sossa, Virginia Abello, Henry Idrobo, Domingo Saavedra, Guillermo Quintero, Lina Gaviria, Rigoberto Gomez, Monica Osuna Pérez, Alicia Henao-Uribe, Luz del Carmen Tarín Arzaga, Omar Cantú-Martínez, David Gomez-Almaguer, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Yahveth Cantero-Fortiz, Guillermo J. Ruiz-Arguelles, Eloisa Riva, Isabella Novoa-Caicedo

Blood (2022) 140 (Supplement 1): 7189–7191.

https://doi.org/10.1182/blood-2022-158104

Published: 2022

Journal Articles

Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Blood (2022) 140 (Supplement 1): 6708–6710.

https://doi.org/10.1182/blood-2022-168165

Published: 2022

NARROW

CRLF2 Expression in Mexicans with Acute Lymphoblastic Leukemia across the Age Spectrum

Exploring the Efficacy and Feasibility of Outpatient Blinatumomab Short Cycles in Pediatric Patients with Relapsed/Refractory B-ALL in LMIC: Preliminary Results

The Doses of Post-Transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Can be Reduced

Optimizing Resources: Low-Dose Nivolumab Combinations in the Management of Relapsed/Refractory Hodgkin Lymphoma, a Real-World Experience

Disparities in Phase 3 Leukemia Trials from the Last Decade: A Long Way to Go

Real-World Data on the Clinical Features, Therapy Patterns and Outcomes of 651 Elderly Patients with Diffuse Large B-Cell Lymphoma in Latin America: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Outpatient Low-Dose Venetoclax Plus Azacitidine Vs. Intensive Chemotherapy for Newly Diagnosed Fit Patients with Acute Myeloid Leukemia in a Limited Resource Setting

Lost and Found: A Mixed Methods Study on Treatment Abandonment in Acute Leukemia

Unlocking Global Potential: Education and Funding Opportunities for International Trainees in Hematology

CYP Inhibition and Low-Dose Dasatinib for Chronic Myeloid Leukemia: Preliminary Results of a Promising, Cost-Effective Treatment Option

Autologous HSCT for Multiple Sclerosis Should be Done Early in the Course of the Disease

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Validating the Systemic Inmmune-Inflamation Index (SII) As a Prognostic Biomarker of Overall Survival in Diffuse Large B-Cell Lymphoma: A Retrospective Analyses By the Gruppo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Capizzi Vs HDMTX in the Intermediate Maintenance Phase in Patients with Intermediate-Risk ALL in a 3rd Level Hospital in Northeastern Mexico

Is VTD the Best First Line Therapy for Multiple Myeloma in an Environment with Limited Resources? an Analysis of Outcomes and Costs

Feasibility and Improvement in Survival with a Risk-Adapted Treatment Regimen for Childhood Acute Lymphoblastic Leukemia in a Limited Resource Setting

Hematopoietic Cell Transplantation in First Remission in AML in Mexico: Very Low Rates Derived from Early Relapses and Lack of Access

Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup

Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only